ATRS:NSD-Antares Pharma, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 2.86

Change

0.00 (0.00)%

Market Cap

USD 0.48B

Volume

2.03M

Average Target Price

USD 5.63 (+96.68%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey. Address: 100 Princeton South, Ewing, NJ, United States, 08628

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

N/A

USD76.72B 71.67 54.32
HOLX Hologic, Inc

N/A

USD16.46B 33.63 24.18
MASI Masimo Corporation

N/A

USD12.27B 58.12 41.64
NVCR NovoCure Limited

N/A

USD11.19B 908.17 492.63
XRAY DENTSPLY SIRONA Inc

N/A

USD10.12B 126.19 33.96
RGEN Repligen Corporation

N/A

USD7.66B 255.63 106.33
IRTC iRhythm Technologies, Inc

N/A

USD6.69B N/A N/A
ICUI ICU Medical, Inc

N/A

USD4.16B 50.67 20.53
STAA STAAR Surgical Company

N/A

USD2.56B 342.69 357.57
MMSI Merit Medical Systems, Inc

N/A

USD2.34B 379.20 35.35

ETFs Containing ATRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.15% 13% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.15% 13% F 16% F
Trailing 12 Months  
Capital Gain -19.44% 23% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.44% 23% F 33% F
Trailing 5 Years  
Capital Gain 49.74% 42% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.74% 42% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 43.49% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.49% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 70.54% N/A N/A N/A N/A
Risk Adjusted Return 61.66% N/A N/A N/A N/A
Market Capitalization 0.48B 50% F 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.20 43% F 16% F
Price/Book Ratio 8.03 25% F 16% F
Price / Cash Flow Ratio -44.75 91% A- 92% A-
EV/EBITDA 37.51 41% F 18% F
Management Effectiveness  
Return on Equity 11.24% 75% C 80% B-
Return on Invested Capital 1.25% 59% F 49% F
Return on Assets 4.57% 72% C- 82% B-
Debt to Equity Ratio 74.12% 21% F 33% F
Technical Ratios  
Short Ratio 4.35 44% F 38% F
Short Percent 2.79% 72% C- 54% F
Beta 1.24 47% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.